Skip to main content
Equibles

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

Position in SLS — SELLAS Life Sciences Group, Inc.

CIK 884546 SAN FRANCISCO, CA
Back to SLS Full portfolio

Position in SLS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$8,339,518
+$6,306,564 QoQ
Shares Held
565,008
+17.6% QoQ
Ownership
0.280%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#18
of 192 holders
Holding Since
Sep 2022
16 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SLS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CHARLES SCHWAB INVESTMENT MANAGEMENT INC holds $7,402,603,842 across 299 Biotechnology names. SLS ranks #112 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 2,041,282 $1,013,966,007
2 REGN
Regeneron Pharmaceuticals, Inc.
 846,306 $527,705,642
3 RVMD
Revolution Medicines, Inc.
 1,917,025 $359,020,441
4 MRNA
Moderna, Inc.
 4,838,884 $338,867,045
5 ALNY
Alnylam Pharmaceuticals, Inc.
 755,377 $227,391,137
6 INCY
Incyte Corp
 1,692,439 $191,854,884
7 RPRX
Royalty Pharma plc
 3,083,528 $172,893,414
8 CYTK
Cytokinetics Inc
 1,565,781 $133,388,883

All Filings in SLS

Export CSV
16 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $8,339,518 565,008
2026-03-31 $2,032,954 480,604
2025-12-31 $1,539,671 408,401
2025-09-30 $473,510 294,106
2025-06-30 $644,092 294,106
2025-03-31 $17,537 16,238
2024-12-31 $16,887 16,238
2024-09-30 $20,297 16,238
2024-06-30 $19,323 16,238
2024-03-31 $16,400 16,238
2023-12-31 $17,212 16,238
2023-09-30 $26,630 16,238
2023-06-30 $25,493 16,238
2023-03-31 $23,220 16,238
2022-12-31 $38,321 16,238
2022-09-30 $32,800 16,238